These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recognition of bacterial glycosphingolipids by natural killer T cells. Kinjo Y; Wu D; Kim G; Xing GW; Poles MA; Ho DD; Tsuji M; Kawahara K; Wong CH; Kronenberg M Nature; 2005 Mar; 434(7032):520-5. PubMed ID: 15791257 [TBL] [Abstract][Full Text] [Related]
4. CD1d-restricted NKT cell activation enhanced homeostatic proliferation of CD8+ T cells in a manner dependent on IL-4. Ueda N; Kuki H; Kamimura D; Sawa S; Seino K; Tashiro T; Fushuku K; Taniguchi M; Hirano T; Murakami M Int Immunol; 2006 Sep; 18(9):1397-404. PubMed ID: 16914507 [TBL] [Abstract][Full Text] [Related]
5. Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide. Tulley JM; Palmer JL; Gamelli RL; Faunce DE Shock; 2008 Feb; 29(2):269-77. PubMed ID: 17693934 [TBL] [Abstract][Full Text] [Related]
6. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Wu D; Zajonc DM; Fujio M; Sullivan BA; Kinjo Y; Kronenberg M; Wilson IA; Wong CH Proc Natl Acad Sci U S A; 2006 Mar; 103(11):3972-7. PubMed ID: 16537470 [TBL] [Abstract][Full Text] [Related]
7. Immediate antigen-specific effector functions by TCR-transgenic CD8+ NKT cells. Wingender G; Berg M; Jüngerkes F; Diehl L; Sullivan BA; Kronenberg M; Limmer A; Knolle PA Eur J Immunol; 2006 Mar; 36(3):570-82. PubMed ID: 16506291 [TBL] [Abstract][Full Text] [Related]
8. NKT cells: T lymphocytes with innate effector functions. Van Kaer L Curr Opin Immunol; 2007 Jun; 19(3):354-64. PubMed ID: 17428648 [TBL] [Abstract][Full Text] [Related]
9. Thymocyte expression of cathepsin L is essential for NKT cell development. Honey K; Benlagha K; Beers C; Forbush K; Teyton L; Kleijmeer MJ; Rudensky AY; Bendelac A Nat Immunol; 2002 Nov; 3(11):1069-74. PubMed ID: 12368909 [TBL] [Abstract][Full Text] [Related]
13. Syntheses of biotinylated alpha-galactosylceramides and their effects on the immune system and CD1 molecules. Sakai T; Naidenko OV; Iijima H; Kronenberg M; Koezuka Y J Med Chem; 1999 May; 42(10):1836-41. PubMed ID: 10346936 [TBL] [Abstract][Full Text] [Related]
14. [A specific ligand of V alpha 14 NKT cells and its presentation]. Harada M; Taniguchi M Tanpakushitsu Kakusan Koso; 2003 Jun; 48(8 Suppl):1126-32. PubMed ID: 12807019 [No Abstract] [Full Text] [Related]
15. Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte. Rhost S; Löfbom L; Rynmark BM; Pei B; Månsson JE; Teneberg S; Blomqvist M; Cardell SL Eur J Immunol; 2012 Nov; 42(11):2851-60. PubMed ID: 22777932 [TBL] [Abstract][Full Text] [Related]
16. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Wu D; Xing GW; Poles MA; Horowitz A; Kinjo Y; Sullivan B; Bodmer-Narkevitch V; Plettenburg O; Kronenberg M; Tsuji M; Ho DD; Wong CH Proc Natl Acad Sci U S A; 2005 Feb; 102(5):1351-6. PubMed ID: 15665086 [TBL] [Abstract][Full Text] [Related]
17. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Major AS; Wilson MT; McCaleb JL; Ru Su Y; Stanic AK; Joyce S; Van Kaer L; Fazio S; Linton MF Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2351-7. PubMed ID: 15472130 [TBL] [Abstract][Full Text] [Related]
18. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. Fujio M; Wu D; Garcia-Navarro R; Ho DD; Tsuji M; Wong CH J Am Chem Soc; 2006 Jul; 128(28):9022-3. PubMed ID: 16834361 [TBL] [Abstract][Full Text] [Related]
19. Increased infiltration of CD1d and natural killer T cells in periodontal disease tissues. Amanuma R; Nakajima T; Yoshie H; Yamazaki K J Periodontal Res; 2006 Feb; 41(1):73-9. PubMed ID: 16409258 [TBL] [Abstract][Full Text] [Related]
20. CD1d-restricted NKT regulatory cells: functional genomic analyses provide new insights into the mechanisms of protection against Type 1 diabetes. Mi QS; Meagher C; Delovitch TL Novartis Found Symp; 2003; 252():146-60; discussion 160-4, 203-10. PubMed ID: 14609217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]